ReviewFrontiers in oncology2022
Gut Microbes in Gynecologic Cancers: Causes or Biomarkers and Therapeutic Potential.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Orchestrating the gut microbiota-mitochondrial-immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies.Frontiers in reproductive health · 2026Review
- Microbiome-host interactions in locally advanced cervical cancer: the impact on chemoradiotherapy treatment outcomes and toxicity.Frontiers in immunology · 2026Review
- The role of dysbiosis in shaping host immunity in endometrial cancer development.Frontiers in immunology · 2025Review
- The impact of altered gut microbiota and lipid metabolism on the progression of endometrial cancer in overweight populations.Frontiers in endocrinology · 2025Article
- Obesity and cancer: unravelling the microbiome's hidden role.Frontiers in nutrition · 2025Review
- Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value.NPJ biofilms and microbiomes · 2024Review
- The Gut Microbiome in Aging and Ovarian Cancer.Aging and cancer · 2024Article
- Review
- Gynecological Cancers and Microbiota Dynamics: Insights into Pathogenesis and Therapy.International journal of molecular sciences · 2024Review
- Review
- Association between diabetes and cancer. Current mechanistic insights into the association and future challenges.Molecular and cellular biochemistry · 2023Review
- Gut Microbiome Dysbiosis in Patients with Endometrial Cancer vs. Healthy Controls Based on 16S rRNA Gene Sequencing.Current microbiology · 2023Article
- Female reproductive tract-organ axes.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human intestine is home to a variety of microorganisms. In healthy populations, the intestinal flora shares a degree of similarity and stability, and they have a role in the metabolism, immunological response, and physiological function of key organs. With the rapid advent of high-throughput sequencing in recent years, several researchers have found that dysbiosis of the human gut microflora potentially cause physical problems and gynecological malignancies among postmenopausal women. Besides, dysbiosis hinders tumor treatment. Nonetheless, the importance of maintaining homeostatic gut microbiota and the effective use of probiotics in the treatment of gynecological malignancies should not be disregarded. Moreover, intestinal flora regulation and the involvement of probiotics as well as associated biologically active substances in gynecological malignancies could be an adjuvant treatment modality related to surgery and chemoradiotherapy in the future. Herein, this article aims to review the potential relationship between gut microorganisms and postmenopausal status as well as gynecologic malignancies; then the relationship between gut microbes and early screening as well as therapeutic aspects. Also, we describe the role of probiotics in the prevention, treatment, and prognosis of gynecologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.